Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Imbruvica
Ibrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), a key signaling molecule in the B-cell receptor signaling pathway. It is used to treat certain types of B-cell cancers by blocking the growth and spread of malignant B cells. Ibrutinib is classified as a kinase inhibitor and specifically a BTK inhibitor.
For the treatment of certain B-cell cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia.
Severe bleeding events, infections, atrial fibrillation, and second primary malignancies have been reported. Use with caution in patients with a history of bleeding or infection.
Outcome:
Increased bleeding risk
Mechanism:
Ibrutinib inhibits platelet function.
Outcome:
Increased risk of hypotension
Mechanism:
Additive hypotensive effects.
Outcome:
May decrease ibrutinib absorption
Mechanism:
Changes in gastric pH.
Most likely new formulation: Subcutaneous injection (2025, 60% confidence)
Based on clinical trial data and post-marketing surveillance, there is a low likelihood of additional black box warnings being issued within the next 2 years (15% confidence).
Kinase Inhibitor, BTK Inhibitor
Pyrazolopyrimidine